Targeting a relapse causing protein to treat childhood acute myeloid leukaemia
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
Finding out how infant leukaemia cells interact with the immune system
Understanding how leukaemia cells enlist immune system cells to help them survive chemotherapy.
Understanding how blood cancer develops and comes back after treatment in babies
Investigating how a protein changes the way leukaemia cells behave in babies.
How do DNA cutting errors lead to relapsed childhood leukaemia
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.
Identifying a new blood cancer to improve the outlook for leukaemia patients
Looking at a new subtype of leukaemia, called CML-like Ph+ALL, to see how best to diagnose and treat it.
How do leukaemia stem cells talk to the immune system in juvenile myelomonocytic leukaemia?
Find out how JMML cells are able to switch off the immune system, causing relapse.
Understanding why some childhood blood cancers are incurable
Using models to find out how high risk leukaemia cells grow and become resistant to treatment.
What factors affect the survival of children and young people with high-risk acute lymphoblastic leukaemia?
Finding out what makes ALL more high-risk, such as age of diagnosis or type of initial treatment.
Stopping drug resistant processes in T-cell acute lymphoblastic leukaemia
Developing a test to select patients who can be treated with a new medicine that prevents steroid resistance.